Literature DB >> 3840627

A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB Study.

W C Wood, R B Weiss, D C Tormey, J F Holland, P H Henry, L A Leone, S Rafla, R T Silver, R W Carey, G J Lesnick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3840627     DOI： 10.1007/bf01655185

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  9 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Cancer of the breast: size of neoplasm and prognosis.

Authors:  B Fisher; N H Slack; I D Bross
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

Review 3.  Adjuvant systemic therapy for resectable breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

4.  Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.

Authors:  H Brincker; H T Mouridsen; K W Andersen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.

Authors:  A Howell; H Bush; W D George; J M Howat; D Crowther; R A Sellwood; R D Rubens; J L Hayward; R D Bulbrook; I S Fentiman
Journal:  Lancet       Date:  1984-08-11       Impact factor: 79.321

6.  A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.

Authors:  D C Tormey; V E Weinberg; J F Holland; R B Weiss; O J Glidewell; M Perloff; G Falkson; H C Falkson; P H Henry; L A Leone
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

7.  Adjuvant chemotherapy in stage-II breast cancer: an overview of the NSABP clinical trials.

Authors:  N Wolmark; B Fisher
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.

Authors:  G P Canellos; S J Pocock; S G Taylor; M E Sears; D J Klaasen; P R Band
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

9.  Adjuvant chemotherapy of breast cancer.

Authors:  R G Cooper; J F Holland; O Glidewell
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860
  9 in total
  3 in total

1.  Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.

Authors:  Ya-Chen Tina Shih; Wenli Dong; Ying Xu; Ruth Etzioni; Yu Shen
Journal:  Ann Intern Med       Date:  2021-02-09       Impact factor: 25.391

2.  Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Authors:  Charlotte Hsieh Ahern; Yu Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

3.  Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.

Authors:  C H Ahern; Y-C T Shih; W Dong; G Parmigiani; Y Shen
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.